15.95
+1.01%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Personalis
From its filings with the US Securities and Exchange Commission
Personalis is based in Fremont, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PSNL. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $69.6m and a net loss of $81.3m. At that date it held total assets of $334.2m and shareholders' equity of $261.2m.
Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. Our testing services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and clinical trials. We also provide whole exome sequencing services for other diagnostic companies and whole genome sequencing services for population sequencing initiatives.
We perform our testing services in a large-scale, high-quality, Clinical Laboratory Improvement Amendments of 1988 ("CLIA") certified and College of American Pathologists (“CAP”) accredited, laboratory located in our 100,000 square foot headquarters in Fremont, California. We were incorporated under the laws of the state of Delaware in 2011 under the name Personalis, Inc. and became a publicly-traded company in 2019.
NeXT Personal is a tumor-informed liquid biopsy test for detection of MRD and recurrence monitoring, in solid tumor cancers. It delivers industry-leading, ultra-high sensitivity, which we believe allows for detection of cancer recurrence earlier than other technologies.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 20 Jun 2019
- Employees
- 259
- Website
- personalis.com ↗
- Head office
- 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Karin EasthamIndependent Chairman of the Board$165,810
- Mr. Christopher HallPresident, Chief Executive Officer, Director, since 2022$1.5m
- Mr. Aaron TachibanaChief Financial Officer, Chief Operating Officer$1.0m
- Dr. Richard ChenExecutive Vice President - Research and Development, Chief Medical Officer$989,394
- Mr. Stephen MooreSenior Vice President, Chief Legal Officer, and Corporate Secretary$674,279
- Ms. Olivia BloomIndependent Director$110,487
- Mr. A. Blaine BowmanIndependent Director$110,810
- Mr. Woodrow MyersIndependent Director$98,310
- Ms. Lonnie ShoffIndependent Director$93,310
- Dr. Kenneth WidderIndependent Director$90,810
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 45
- Environment
- 48
- Social
- 49
- Governance
- 37
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Personalis Inc, being a leading genomic data company, possesses several strengths that give it a competitive edge in the market. These strengths include:
Weaknesses
- Despite its strengths, Personalis Inc also faces certain weaknesses that need to be addressed to maintain its competitive position:
Opportunities
- Personalis Inc has several opportunities that it can capitalize on to further grow and expand its business:
Threats
- Personalis Inc should also be aware of potential threats that could impact its business and take necessary precautions:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.